The functional heterogeneity of uridine diphosphateglucuronosyltransferase (UDPGT) and its deficiency in human liver were investigated. The monoclonal antibody (MAb) WP1, which inhibits bilirubin and phenol-glucuronidating activity, was used to immunopurify UDPGTs from human liver. Purified UDPGTs were injected into mice to obtain new MAbs. Immunoblotting of microsomes with MAb HEB7 revealed at least three polypeptides in liver (56, 54, and 53 kD) and one in kidney (54 kD). In liver microsomes from four patients (A, B, C, and D) with Crigler-Najjar syndrome type I (CN type I), UDPGT activity towards bilirubin was undetectable (A, B, C, and D) and activity towards phenolic compounds and 5-hydroxytryptamine either reduced (A and B) or normal (C and D). UDPGT activity toward steroids was normal. Immunoblot studies revealed that the monoclonal antibody WP1 recognized two polypeptides (56 and 54 kD) in liver microsomes from patient A and none in patient B. With HEB7 no immunoreactive polypeptides were seen in these two patients. Patient C showed a normal banding pattern and in patient D only the 53-kD band showed decreased intensity. These findings suggest considerable heterogeneity with regard to the expression of UDPGT isoenzymes among CN type I patients. (J. Clin.
Introduction
Uridine diphosphate-glucuronosyltransferase (UDPGT,' EC 2.4.1.17) is a membrane-bound enzyme system concentrated in the lipid bilayer of the endoplasmic reticulum in hepatocytes and cells of intestine, kidney, and other tissues (1) . It catalyzes the transfer of glucuronic acid from uridine 5'-di-phosphate-glucuronic acid to compounds of either endogenous or exogenous origin such as bilirubin, steroids, phenolic compounds, and a wide range of different drugs.
Patients with the Crigler-Najjar syndrome type I (CN type I) have an inheritable complete deficiency of UDPGT activity towards bilirubin which results in a severe nonhemolytic unconjugated hyperbilirubinemia (2) . These patients often die of kernicterus in infancy or early adulthood. The mutant Gunn rat also lacks hepatic UDPGT activity for bilirubin and forms an animal model for the CN type 1 (3, 4) . In addition, UDPGT activity towards phenolic compounds and digitoxigenin monodigitoxoside has been reported to be decreased in the Gunn rat (5) (6) (7) and in CN type I liver (8) .
Most of the current knowledge on various aspects of UDPGT is based on studies of the enzyme system present in rat liver. The differential induction and development profiles of substrate-specific UDPGT activities are indirect indications for the existence of multiple isoenzymes of UDPGT in the rat (9-1 1). Chromatofocusing of rat liver microsomal UDPGT activities revealed the existence of at least five different isoenzymes (12) (13) (14) , and recently two more isoenzymes have been purified (15, 16) . Two of these isoenzymes are a bilirubin-and phenol-UDPGT. Furthermore, structural information has been obtained by cDNA cloning of several isoenzymes (17) (18) (19) (20) . Less information is available on the multiplicity of UDPGT in human tissues. Purification oftwo isoenzymes and the cloning of two cDNAs has been reported (21-23). Recently it has been shown that 4-methylumbelliferone (4-MU), a substrate for the purified and cloned human liver phenol-UDPGT, could not inhibit the glucuronidation of bilirubin by human liver microsomes (24) . This suggests that in human liver separate bilirubin-and phenol-UDPGT isoenzymes also exist.
Monoclonal antibodies are a powerful tool for the characterization of heterogeneous enzyme systems (25) . The first reported monoclonal antibody against UDPGT, which is designated WPl, was produced against UDPGT of human origin (26) . This antibody inhibits the glucuronidation of bilirubin, paranitrophenol (PNP), and 4-MU but not that ofsteroids like testosterone. Furthermore, several polypeptides reacting with this antibody are visualized by immunoblotting experiments after SDS-PAGE (27) .
In the present study we have used this and a new monoclonal antibody to characterize the defect in livers from several CN type I patients.
Methods
Materials. Cyanogen bromide-activated Sepharose 4B beads were purchased from Pharmacia (Uppsala, Sweden). Goat anti-mouse and goat anti-rabbit antibodies conjugated with either horseradish peroxidase or alkaline phosphatase were from Bio-Rad Laboratories (Richmond, CA). Nitrocellulose membranes were from Schleier & Schull (Kassel, FRG). All reagents used were of analytical quality.
Tissue samples. Normal human liver was obtained from surgical resection specimens. Human kidney specimens came from autopsy performed within 12 h after death. Liver material of four CN type I patients was obtained after orthotopic liver transplantation (patients A, B, C, and D). Some clinical data of these patients are given in Table  I . All human specimens were stored at -70'C.
Isolation of microsomes and homogenates from human liver and kidney was performed as previously described (25) . The microsomal pellets were resuspended in 50 mM Tris-HCI, pH 7.8, 250 mM sucrose, and 2 mM EDTA and frozen as aliquots at -20'C until use within 3 mo.
Enzyme assays. Glucuronidation of bilirubin, PNP, 4-MU, 5-hydroxytryptamine (5-HT), estrone, fl-estradiol, androsterone, testosterone, and estriol was measured as described elsewhere (21, 28-30) and NADPH-cytochrome c reductase activity according to Williams and Kamin (31 Immunopurified human UDPGTs were injected into mice and rabbits to obtain new monoclonal and polyclonal antibodies. Screening and subsequent cloning of the hybrid cells resulted in a hybridoma clone HEB7, secreting an antibody that reacts in the ELISA with immunopurified UDPGT from human liver. The fractions obtained by the described procedure were also tested for their immunoreactivity with HEB7. The fractions that reacted with WPl also reacted with HEB7. More importantly, HEB7 did not react with any of the polypeptides present in the run-through of the column, indicating that HEB7 reacts with no other polypeptides than those immunopurified on the WPI column.
Characterization activity towards PNP, 4-MU, and 5-HT was decreased in microsomes from patients A and B but not in microsomes from patients C and D. In all patients glucuronidation of estriol, estrone, testosterone, and androsterone was within the range of control values (Table II) . As a microsomal marker and test for the quality of the livers NADPH cytochrome c reductase activity was measured. No significant difference between controls and patients could be observed. The significance of the lowered activity towards PNP and 4-MU in patients A and B was supported by immunoprecipitation experiments: no UDPGT activity towards PNP and 4-MU could be precipitated by WPl (Fig. 1) . However, the normal activity in patients C and D could be precipitated though to a lesser extent as in controls (Fig. 1) .
The defect in CN type I patients was analyzed further by immunoblot analysis. Total homogenates from normal human liver and livers from the four CN type I patients were subjected to SDS-PAGE followed by blotting of the resolved proteins to nitrocellulose. The monoclonal antibody WPl was used as antibody probe. Within the limits of resolution, normal liver revealed at least four immunoreactive polypeptides of 57, 56, 54, and 53 kD (Fig. 3, lanes 1-3) . The difference in staining intensity between the three control preparations is assumed to be caused by individual variation in the expression of UDPGTs. This is in accordance with the high variation in UDPGT activities found in control livers (see Table I ).
In patient A only two bands were visible (56 and 54 kD) and with strongly decreased intensity. In patient B none of these polypeptides were detectable. Patient C and D showed a different picture: patient C showed a pattern similar to controls and in patient D only the lower bands (53 and 54 kD) were decreased in staining intensity.
When microsomes instead of homogenates were used the following picture emerged with patient A: WPI recognized with decreased staining intensity a 56-and 54-kD band but the Uridine Diphosphate-Glucuronosyltransferase Expression in Crigler-Najjar Syndrome Type I 1201 A (Fig. 4 , panels I and II, lane 6). As stated above UDPGTs from patient A reacted differentially with our two monoclonal antibodies, which suggests a structural alteration in the polypeptides normally recognized by these antibodies. To verify this observation we purified UDPGTs from solubilized liver microsomes ofpatient A using a column of immobilized WP1. In an ELISA WPl reacted normally with this UDPGT preparation. However, no immunological cross-reaction was observed when HEB7 was used as the antibody (Fig. 5) . This again points to structural mutation of the WP 
Discussion
Immunopurification as reported in this paper is a powerful method for single-step, preparative purification of UDPGTs from human tissues. We were also able to obtain a pure 54-kD polypeptide from human kidney (data not shown). However, the method described here does not allow the purification of biologically active UDPGTs. This is probably due to extensive delipidation by the high concentrations of Triton X-100 used during chromatography (36, 37) . By using the immunopurified human hepatic UDPGTs as antigen, a new antibody was obtained with characteristics different from the original monoclonal antibody WP 1. The specificity of the monoclonal antibody HEB7 was addressed by WP I immunoaffinity chromatography. This clearly showed that the monoclonal antibody HEB7 only reacted with proteins bound by WPl and not with the polypeptides in the runthrough of this column. In addition to this, the specificity of this monoclonal antibody for UDPGT was emphasized by the binding to partially purified phenol-and bilirubin-UDPGT from rat liver microsomes. These polypeptides could not be detected in Gunn rat liver microsomes (data not shown).
Using WP 1, in immunoblot analysis of normal human liver microsomes at least three polypeptides with a molecular mass of 56, 54, and 53 kD were detected. When liver homogenates were used instead of microsomes the resolution was found to be much better resulting in an extra 57-kD band. Using microsomes, this polypeptide is not or poorly separated from the 56-kD polypeptide. With HEB7, immunoblot analysis of normal human hepatic and renal microsomes revealed a pattern of immunoreactive polypeptides similar to WPl.
Renal microsomes showed a single 54-kD polypeptide with both monoclonal antibodies and as bilirubin glucuronidating activity is absent in human kidney (27) , the 53-or the 57-kD polypeptide in human liver might represent the bilirubin-UDPGT isoenzyme. Microsomes from human kidney are active towards phenolic compounds (27) A possible explanation for the observations in patients A and B is that bilirubin and phenolic compounds are conjugated by one isoenzyme, which shows microheterogeneity on SDS-PAGE and which is absent or mutated in these two patients. However, a number ofconsiderations argue against this explanation: for rat liver it has been shown that the purified bilirubin-conjugating isoenzyme has little or no activity towards PNP and vice versa (13) . Furthermore, glucuronidation of bilirubin takes place at carboxyl groups, whereas phenolic compounds like PNP are glucuronidated at aromatic hydroxyl groups. It is rather unlikely that conjugation of these different groups is catalyzed by the same active site. Furthermore, Miners et al. (24) could not show inhibition of bilirubin glucuronidation in human liver microsomes by 4-MU, a substrate for the purified and cloned phenol-UDPGT. Finally, as discussed above there is no bilirubin glucuronidation in human kidney while phenol conjugation is present (27) and precipitable with WP1 (data not shown). These arguments suggest that bilirubin and phenol glucuronidation in human liver is catalyzed by separate isoenzymes.
Abe et al. (38) were able to partially purify an isoenzyme from rat liver that is specific for 5-HT (38) . For human liver the existence of a distinct 5-HT isoenzyme has been postulated (39, 40) ; based on these data the decrease of 5-HT UDPGT activity suggests that yet another isoenzyme is affected in patients A and B.
From the results described in this study it can be concluded that at least two and maybe three different UDPGT isoenzymes are affected in patients A and B. In contrast, in patients C and D only one isoenzyme appears to be affected. Recently liver tissue of a fifth patient was analyzed. The expression of UDPGTs was found to be similar to patient B.
A structural mutation in more than one isoenzyme could be explained by assuming different simultaneous mutations in more than one gene. Since in patient A the mutations in both polypeptides are identical namely absence of the epitope for HEB7, this would implicate that both genes carry very similar or identical mutations. Two possible genetic mechanisms have to be considered. Gene conversion of two different but homologous genes of which one is mutated is a possible explanation. This mechanism has been suggested for some cases of steroid14a-hydroxylase deficiency (41, 42) in which a normal and a pseudogene are involved. Another possible explanation for our observations is posttranscriptional and/or posttranslational modification of a single gene product which gives rise to bilirubin-and phenol-UDPGT isoenzymes. Recently an alternative splicing mechanism has been shown to exist for the cytochrome P-450-PB-7 gene. Two mRNAs encoding two different proteins are generated by this mechanism (43) . Although the reported cDNAs do not clearly suggest such a mechanism, this possibility cannot be ruled out because a cDNA for bilirubin-UDPGT has not been cloned yet, either from human or rat liver cDNA libraries.
The results of patient C and D can be explained by each of the mechanisms discussed above: in case ofseparate genes only the bilirubin-UDPGT gene is mutated. In case of posttranscriptional and/or posttranslational modification only that part of the gene that is incorporated into the bilirubin isoenzyme may be mutated.
